Scarica l'app Stockscreener
5.25
1.32%
-0.07
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Savara Inc Borsa (SVRA) Ultime notizie
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SVRASavara Inc Latest Stock News & Market Updates - Stock Titan
Savara (NASDAQ:SVRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Decoding Savara Inc (SVRA): A Strategic SWOT Insight - GuruFocus
Savara Inc. 2025 Annual Report: MOLBREEVI Clinical Progress, Business Strategy, and Key Risk Factors - Minichart
Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee - MyChesCo
Savara (SVRA) Advances with MOLBREEVI, Boosting Financial Positi - GuruFocus
Savara Signs Long-Term Lease for New Headquarters - TipRanks
Savara (NASDAQ: SVRA) details new Yardley headquarters lease terms - Stock Titan
SVRA: Regulatory progress and robust cash position set the stage for a potential 2026 launch - TradingView
Savara receives FDA priority review for rare lung disease drug - Investing.com
Savara : Corporate Presentation - marketscreener.com
Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss - marketscreener.com
Savara Q4 net loss widens as expenses rise - TradingView
Savara 10-K: $0M Revenue, $0.00 EPS; $118.8M Net Loss - TradingView
SVRA: Net loss increased to $118.8M in 2025 as MOLBREEVI advanced toward FDA review and commercialization - TradingView
MOLBREEVI strategy and FDA Priority Review drive Savara (NASDAQ: SVRA) - Stock Titan
BRIEF-Savara Q4 Net Income USD -32.236 Million - TradingView
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - The Joplin Globe
Rosalind Advisors Inc. Has $14.28 Million Position in Savara Inc. $SVRA - MarketBeat
Aug Shorts: Why is Savara Inc stock going down2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
How FDA’s No-Advisory-Committee Path for MOLBREEVI Could Shape Savara (SVRA) Investors’ Outlook - simplywall.st
FY2030 Earnings Forecast for Savara Issued By HC Wainwright - MarketBeat
Savara receives FDA day 74 letter for autoimmune PAP drug - Investing.com Nigeria
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
Savara Inc. Announces Equity Awards for New Employees - MSN
Savara receives FDA day 74 letter for autoimmune PAP drug By Investing.com - Investing.com Australia
Savara (SVRA) Advances MOLBREEVI Application with FDA and EMA - GuruFocus
Savara Provides Regulatory Update on the MOLBREEVI* Development P - The National Law Review
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Benzinga
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVIWhat's Changed - Yahoo Finance
Savara Inc (NASDAQ: SVRA) recently announced that it has received a Day 74 letter from the U.S. Food and Drug Administration (FDA). - Bitget
Savara Inc. Confirms Participation in 2026 Citizens Life Sciences Conference Focused on Rare Respiratory Diseases - geneonline.com
Savara Announces Participation in 2026 Citizens Life Sciences Conference - Business Wire
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MyChesCo
Why Savara (SVRA) Is Up 5.4% After FDA Grants Priority Review To MOLBREEVI Application - simplywall.st
Savara Inc. (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears - MarketBeat
SVRA PE Ratio & Valuation, Is SVRA Overvalued - Intellectia AI
Assessing Savara (SVRA) Valuation After FDA Priority Review For MOLBREEVI - simplywall.st
Savara, Inc. (SVRA) Investor Outlook: An 81% Upside Potential In Rare Respiratory Disease Treatment - DirectorsTalk Interviews
Savara Announces Participation in Upcoming Investor Healthcare Conferences - Business Wire
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Citizens reiterates Savara stock rating on likely FDA approval - Investing.com Nigeria
Is FDA Priority Review for MOLBREEVI Reshaping the Investment Case for Savara (SVRA)? - simplywall.st
Savara Grants Inducement Equity Awards to New Employee - MyChesCo
Citizens reiterates Savara stock rating on likely FDA approval By Investing.com - Investing.com India
FDA accepts Savara’s drug application for rare lung disease By Investing.com - Investing.com Australia
Savara, Inc. (SVRA) Stock Analysis: Biotech Player With An 89% Upside Potential - DirectorsTalk Interviews
Savara (SVRA) Gains Priority Review for Molbreevi by FDA - GuruFocus
FDA accepts Savara’s drug application for rare lung disease - Investing.com India
Savara's Molbreevi BLA for Autoimmune Pulmonary Alveolar Proteinosis Accepted for FDA Review - marketscreener.com
Savara (SVRA) Gains FDA Priority Review for Molbreevi BLA - GuruFocus
FDA Grants Priority Review to Savara's (SVRA) Molbreevi BLA - GuruFocus
Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - The AI Journal
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):